Skip to content

MassBio

Massachusetts Biotechnology Council

Open search form
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
  • Resources
    • Industry Snapshot
    • MassBioHub – Conference Center
    • COVID-19 Resource Center
    • Innovation Services
    • Policy & Advocacy
    • Economic Development
    • Career Center
  • Events
    • Events Calendar
    • Overview of Events
    • Get Involved
  • Membership
    • Member Directory
    • Benefits of Membership
    • Pricing
    • Virtual Member Benefits
    • Member News
    • Become a Member
    • Pay Company Dues
  • MassBio Edge
    • MassBio Edge
    • Preferred Partners
    • Employee Rewards
    • Edge Benefits
  • Initiatives
    • State of Possible 2025 Report
    • Equity, Diversity, and Inclusion
    • Open Letter 2.0 – CEO Pledge for ED&I
    • Value of Health
    • Digital Health
    • BioReady Communities
  • About Us
    • About Us
    • Sponsorship Opportunities
    • Staff
    • Board of Directors
    • MassBioEd
    • FAQs
    • Contact Us
  • News
    • News & Thought Leadership
    • State of Possible Podcast
  • Sign In/Create Account
  • Pay Company Dues
  • Become a Member
Open search form

Member Directory

Click to Open Main Menu

Elicio Therapeutics

Life Sciences | Drug Development
Cambridge, MA (857) 209-0056 Website

Overview

Elicio is committed to transforming the lives of patients and their families by re-engineering the body’s immune response to cancer. By combining expertise in materials science and immunology, Elicio is engineering potent vaccines and immuno-therapies for an array of aggressive cancers. The Elicio Amphiphile platform enables precise targeting and delivery of immunogens directly to the lymphatic system, the “brain center” of the immune response, to significantly amplify and enhance the body’s own system of defenses, to defeat cancer and stop its recurrence. This substantially enhanced anti-tumor functionality and long-term protective memory could unlock the full potential of the human immune response to eliminate cancer. Elicio’s lead Amphiphile vaccines targeting pancreatic, colorectal, and head and neck cancer will begin initial patient studies in early 2020. Elicio was founded to expand and apply the ground-breaking Amphiphile technology invented and developed in the labs of Darrell Irvine Ph.D., Professor of Biological Engineering and Materials Sciences and Howard Hughes Investigator, at the Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology. Preclinical studies have demonstrated that Elicio’s Amphiphile vaccines target and concentrate in the lymph nodes resulting in unprecedented tumor-specific immune responses and durable cures of aggressive tumor models in mice.

Company News

News

Elicio Therapeutics Announces FDA Clearance of IND Application for ELI-002 — A Therapeutic Vaccine Targeting Mutated KRAS Cancers

Feb 23, 2021

Posted by Elicio Therapeutics

News

Elicio Therapeutics Completes $33 Million Series B Financing

Oct 02, 2019

Posted by Elicio Therapeutics

See all Members

Massachusetts Biotechnology Council

700 Technology Square, 5th Floor
Cambridge, MA 02139
617.674.5100

  • Contact
  • Privacy Policy
  • Fulfillment Policy
  • © 2021 All Rights Reserved